GlassScriptPhysician profile
Steven A Sussman
NPI 1043283690
$3,704.14
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $93.12 · 2021: $365 · 2022: $2,838.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,152.50 | 2021-2022 | |
| Scynexis, INC. | $1,050.00 | 2022 | |
| Pfizer INC. | $75.94 | 2019-2020 | |
| Abbvie INC. | $68.51 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.24 | 2019 | |
| Exeltis, USA INC. | $50.70 | 2019-2020 | |
| Millicent US INC | $50.48 | 2019 | |
| Therapeuticsmd, INC. | $40.86 | 2019-2020 | |
| Allergan, INC. | $37.97 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $26.69 | 2019 | |
| Amag Pharmaceuticals, INC. | $26.54 | 2019 | |
| Covidien LP | $20.64 | 2019 | |
| Sage Therapeutics, LLC | $14.96 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.62 | 2019 | |
| Duchesnay USA Incorporated | $14.49 | 2019 |
8 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sussman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.